Stock Screener App

Frei -

Installieren

7.94

3.52% -0.29

after-market

Handel nachbörslich: 7.91 -0.03 -0.38%

Ars Pharmaceuticals Inc (SPRY)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$8.23

Offen:

$8.23

24-Stunden-Volumen:

2.48M

Relative Volume:

1.56

Marktkapitalisierung:

$788.47M

Einnahmen:

$84.28M

Nettoeinkommen (Verlust:

$-171.30M

KGV:

-4.5703

EPS:

-1.7373

Netto-Cashflow:

$-171.21M

1W Leistung:

+6.94%

1M Leistung:

-5.48%

6M Leistung:

+4.61%

1J Leistung:

-45.32%

1-Tages-Spanne:

$7.91

$8.29

1-Wochen-Bereich:

$7.08

$8.36

52-Wochen-Spanne:

$6.66

$18.90

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Firmenname

Ars Pharmaceuticals Inc

Sektor

Healthcare (1108)

Branche

Biotechnology (618)

Telefon

858-771-9307

Adresse

11682 EL CAMINO REAL, SUITE 300, SAN DIEGO

Mitarbeiter

159

Twitter

Nächster Verdiensttermin

2026-05-15

Neueste SEC-Einreichungen

SPRY's Discussions on Twitter

Compare SPRY vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SPRY Ars Pharmaceuticals Inc	7.94	817.27M	84.28M	-171.30M	-171.21M	-1.7373
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-09	Eingeleitet	Northland Capital	Outperform
2025-11-04	Fortgesetzt	Roth Capital	Buy
2025-09-04	Eingeleitet	Roth Capital	Buy
2025-03-07	Eingeleitet	Scotiabank	Sector Outperform
2025-02-10	Eingeleitet	Oppenheimer	Outperform
2024-08-20	Eingeleitet	Cantor Fitzgerald	Overweight
2024-08-13	Hochstufung	Raymond James	Outperform → Strong Buy
2024-08-12	Bestätigt	Leerink Partners	Outperform
2024-07-25	Eingeleitet	Raymond James	Outperform
2024-03-05	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-02-20	Hochstufung	William Blair	Mkt Perform → Outperform
2023-09-20	Herabstufung	William Blair	Outperform → Mkt Perform
2023-01-31	Eingeleitet	Wedbush	Outperform
2023-01-03	Eingeleitet	William Blair	Outperform
2022-12-13	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten

Number of shareholders of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY - TradingView

SPRY Should I Buy - Intellectia AI

Ars Pharmaceuticals’ Earnings Call Highlights Growth and Risks - TipRanks

ARS Pharmaceuticals: Still A Buy As Neffy Access Improves (NASDAQ:SPRY) - Seeking Alpha

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2026 Earnings Call Transcript - Insider Monkey

SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill

ARS Pharmaceuticals gears up for Q1 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN

ARS Pharma (SPRY) Q1 2026 Earnings Transcript - The Globe and Mail

Why (SPRY) Price Action Is Critical for Tactical Trading - Stock Traders Daily

ARS Pharmaceuticals, Inc. (SPRY) reports Q1 loss, beats revenue estimates - MSN

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by ARS Investment Partners LLC - MarketBeat

ARS Pharmaceuticals Q1 earnings call highlights - MSN

Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY) - The Globe and Mail

ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program - MSN

Transcript : ARS Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 15, 2026 - marketscreener.com

ARS Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat

ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada

ARS Pharma (SPRY) Q4 2025 Earnings Transcript - The Globe and Mail

ARS Pharmaceuticals 2026 Q1 10-Q: Financial Results, neffy™ Commercialization, and Key Risk Factors - Minichart

Rubric Capital (SPRY) reports 8.06% stake; 8,000,000 shares disclosed - Stock Titan

ARS Pharmaceuticals Q1 2026 Results: neffy® Drives $22.7M Revenue, U.S. and Global Expansion Updates - Minichart

ARS Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat

SPRY: Q1 revenue hit $22.7M as neffy adoption surged, with expanded access set to drive further growth - TradingView

Earnings call transcript: ARS Pharmaceuticals misses Q1 2026 EPS forecast, stock drops - Investing.com

ARS Pharmaceuticals Delivers 185% Revenue Growth in Q1 2026 - AlphaStreet

ARS Pharmaceuticals earnings missed by $0.12, revenue topped estimates - Investing.com Canada

ARS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

ARS Pharmaceuticals stock rises 2% on revenue beat despite earnings miss By Investing.com - Investing.com South Africa

ARS Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet

ARS Pharmaceuticals (NASDAQ:SPRY) Reports Revenue Growth in Q1 2026, Net Loss Widens on Commercial Investment - ChartMill

ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion - TipRanks

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance

ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell - Moomoo

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - Investing News Network

ARS PHARMACEUTICALS ($SPRY) Releases Q1 2026 Earnings - Quiver Quantitative

ARS Pharmaceuticals 1Q 2026: Revenue $22.7M, EPS $(0.61) — 10-Q Summary - TradingView

Neffy launch drives ARS Pharmaceuticals (NASDAQ: SPRY) Q1 revenue jump - Stock Titan

ARS Pharmaceuticals stock rises 2% on revenue beat despite earnings miss - Investing.com

Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss - marketscreener.com

ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth - TradingView

Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q1 Revenue $22.7M, vs. FactSet Est of $22.2M - marketscreener.com

ARS Pharmaceuticals (NASDAQ: SPRY) grows neffy sales but posts $60.6M Q1 loss - Stock Titan

Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update - Moomoo

ARS Pharmaceuticals Q1 2026 earnings preview - MSN

What's Driving ARS Pharmaceuticals' Q1 2026 Earnings Narrative - Kavout

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most A - Benzinga

ARS Pharmaceuticals Appoints Donn Casale as New President - The Globe and Mail

ARS Pharma names Donn Casale president - The Pharma Letter

Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates - Yahoo Finance

ARS Pharmaceuticals appoints Donn Casale as president By Investing.com - Investing.com India

Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)

Umsatz

Nettogewinn

Free Cashflow

ENV

ROIV

$29.96

2.98%

INSM

$106.24

3.00%

BNTX

$92.14

1.33%

RPRX

$54.50

1.77%

ONC

$310.25

0.20%

RVMD

$151.56

1.41%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters